查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863072

按藥物類別、劑型、給藥途徑、通路和最終用戶分類的失眠治療市場－2025年至2032年全球預測

Insomnia Drugs Market by Drug Class, Formulation, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，失眠治療市場將成長至 48.7 億美元，複合年成長率為 5.91%。

關鍵市場統計數據
基準年 2024 30.7億美元
預計年份：2025年 32.5億美元
預測年份 2032 48.7億美元
複合年成長率 (%) 5.91%

本文簡要概述了塑造現代失眠治療格局的治療創新、臨床壓力和商業性促進因素。

由於科技進步、患者期望的改變以及監管力度的加大，失眠治療市場正在迅速發展。本執行摘要探討了對藥物研發、臨床實踐、分銷和支付方參與等各相關人員當前及近期決策至關重要的主題。它全面概述了治療方法創新、消費模式的轉變以及支持治療交付的基礎設施，為尋求將投資與新機會相結合的領導者提供了清晰的切入點。

重點，本導言將失眠置於更廣泛的醫療保健背景下進行探討，闡述了合併的精神疾病和心血管代謝疾病如何影響治療方案的選擇和患者的依從性。它重點強調了藥物差異、安全性以及給藥便利性如何日益影響臨床醫生的偏好和患者的接受度。本節概述了用於解讀趨勢的方法論嚴謹性和多角度觀點（臨床、監管和商業性），為後續分析奠定了基礎。我們鼓勵讀者專注於策略意義，而非歷史銷售指標。後續章節將重點闡述可操作的見解，以支援產品組合和市場進入決策。

本文分析了正在重塑失眠藥物研發和應用格局的、模式轉移的臨床進展、支付方期望以及醫療服務創新。

失眠治療領域正經歷一場變革浪潮，其驅動力包括作用機制的創新、安全性期望的提高以及數位化醫療路徑的拓展。針對Orexin受體的新型化合物正在重塑臨床上關於療效和次日起效的討論，促使臨床醫生重新評估處方模式和風險獲益權衡。同時，旨在改善起效時間、持續時間和耐受性的製劑科學進展，正在影響產品在門診和住院環境中的定位。

同時，支付方的嚴格審查和監管指導迫使製藥公司透過真實世界數據和療效比較研究來證明其差異化價值。數位療法和遠端患者監護正在重新定義輔助治療模式，從而實現結合行為療法和藥物療法的階梯式治療方案。此外，以病人為中心的包裝和替代給藥途徑也日益受到重視，成為提高病人依從性的有效途徑。總而言之，這些變化正在重塑競爭格局，刺激對標靶研發的投資，並支持策略合作，從而加速下一代失眠療法的臨床轉化。

2025年關稅調整和貿易趨勢將如何推動失眠治療價值鏈的供應鏈重組、購買多元化和韌性投資

包括2025年實施的關稅調整在內的政策和貿易措施，為製藥企業和經銷商的全球供應鏈規劃引入了新的變數。這些措施影響了部分進口原料藥、輔料和成品藥的成本基礎，促使採購部門重新評估籌資策略和緊急庫存。為此，許多企業正在加速供應商網路多元化，並更加重視近岸外包，以降低貿易波動帶來的風險。

此外，不斷變化的關稅環境也促使各通路的服務交付成本受到更嚴格的審查。醫院藥局和大型零售連鎖店正在審查採購合約和庫存管理通訊協定，以緩解利潤率下降的情況。同時，製造商正在重新評估生產基地選址和供應鏈韌性投資，優先考慮大量生產的靈活性和多基地認證。監管合規性和品質保證要求持續影響這些調整，企業越來越需要在關稅驅動的成本壓力與對可靠性和治療完整性的承諾之間尋求平衡。

全面的細分分析揭示了治療領域特徵、劑型和給藥途徑的差異、分銷動態和最終用戶趨勢等方面的見解，所有這些都可以用來製定目標策略。

細分市場分析揭示了不同治療層級、製劑形式、給藥途徑、分銷管道和終端用戶環境對價值和需求的影響因素。藥物類別包括抗組織胺、苯二氮平類、褪黑素受體促效劑、非苯二氮平類藥物和Orexin受體拮抗劑。在非苯二氮平類藥物中，一些具有重要臨床意義的藥物，例如依佐匹克隆、Zaleplon和Zolpidem，其起效時間和半衰期各不相同，這影響了它們的市場定位。同時，Orexin受體拮抗劑，例如達利多雷沙、倫博雷沙和蘇沃雷沙，為處方醫師的決策帶來了新的療效和耐受性的考量。這些差異導致了不同的臨床評估和推廣策略，有些藥物更適合短期症狀管理，而有些藥物則更適合維持治療。

從膠囊、注射到口服混懸液、舌下片和錠劑，多種劑型選擇影響產品的差異化和患者偏好，而易用性和起效速度則賦予了產品競爭優勢。給藥途徑——靜脈注射、口服、舌下和經皮——進一步影響醫院和門診的用藥情況，以及特定治療方案在基層醫療和急診環境中的可行性。分銷通路細分突顯了藥局、醫院藥局、線上藥局和零售藥局在影響藥物可近性和依從性方面所發揮的作用。在醫院藥局內部，公立和私立機構的採購行為有差異。線上藥局分為一般B2C平台、廠商直銷網站和遠距藥事照護服務，每種平台都有其獨特的監管和商業特徵。零售藥局（連鎖藥局、獨立藥局和超級市場附屬藥局）的多樣性影響著促銷範圍和銷售點互動策略。將門診中心、診所、居家醫療和醫院等終端使用者細分，可凸顯不同的診療路徑。醫院本身又分為公立和私立兩類，各自擁有不同的處方集流程和採購週期。整合這些細分觀點，有助於相關人員更好地協調臨床開發、行銷和分銷策略，從而滿足目標處方醫生和患者的細微需求。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和監管差異要求失眠藥物的取得和分銷策略具有適應性。

區域趨勢持續影響產品策略、監管計劃和分銷網路設計。在美洲，臨床實踐模式以及公立和私立支付方之間的互動影響著藥品目錄的准入，而數位化醫療的普及和遠距藥事照護模式則擴大了門診病人範圍並提升了病人參與。美洲市場的准入考量通常著重於展示產品在實際應用中的功能性和安全性差異，以確保獲得臨床醫生和支付方的青睞。

在歐洲、中東和非洲地區，不同的法規結構和採購環境要求制定適應性強的市場進入策略，以因應各國處方集、公立醫院採購和私部門的差異。這些地區的臨床醫生在處方決策中優先考慮藥物的長期耐受性和合併症情況，而公立和私立醫療系統的報銷途徑可能存在顯著差異。在亞太地區，遠端醫療的快速普及、多樣化的報銷機制以及不斷發展的國內生產能力既帶來了機遇，也帶來了挑戰。相關人員正優先考慮在地化證據的產生、監管協調策略以及與區域經銷商的合作，以應對採購慣例並加速在公立和私立醫療機構中的應用。在所有地區，供應鏈的韌性、與當地監管機構的合作以及符合當地文化的病患教育仍然是成功商業化的關鍵要素。

競爭和企業策略著重於差異化治療方法、數位化協作、生命週期管理以及臨床和商業性優勢的證據產生。

主要企業之間的競爭特點在於，它們專注於有針對性的研發投資、建立合作夥伴關係以及生命週期管理，旨在維持產品的臨床相關性。各公司正利用臨床差異化優勢，例如改善隔日認知功能和降低成癮風險，以更好地向處方醫生和支付方推廣其後期研發和已上市產品。製藥開發商與數位醫療供應商之間的策略聯盟日益普遍，從而能夠整合藥物和行為解決方案，以解決藥物依從性和長期治療效果問題。

此外，一些製造商正在最佳化包裝、患者援助計劃和與專科藥房的合作，以適應特定的分銷管道和終端用戶環境，從而推動商業化。併購和授權合約仍然是拓展產品組合和取得差異化作用戰術性的有效策略。整體競爭格局日益著重於產生核准後證據，包括真實世界研究和註冊研究，以支持產品價值主張並輔助健保報銷談判。在營運方面，各公司正在投資提升供應鏈靈活性和監管專業知識，以加快跨區域市場准入，同時保持高標準的品質和安全。

為產業領導者建立永續競爭優勢提供實用策略指南：整合證據產生、數位整合、彈性供應鏈和個人化商業化

產業領導者應優先考慮整合臨床差異化、切實可行的市場進入策略和穩健的供應鏈設計的方法。首先，他們應投資於有針對性的證據生成，以證明療效比較、患者報告結局和真實世界安全性，從而支持藥品目錄的納入和與支付方的對話。其次，他們應加強與數位醫療服務提供者的合作，創建整合式照護路徑，以提高治療依從性並擴大市場覆蓋範圍，尤其是在門診和居家醫療領域。這種聯合交付模式將增強對臨床醫生和支付方的價值提案。

同時，我們透過供應商多元化和篩選合格的替代製造地來最佳化生產和採購，從而降低貿易和關稅相關中斷的風險。我們利用客製化的價值提案材料和本地真實世界數據，加強與醫院處方集委員會的合作，鼓勵私營和公共部門儘早採用我們的產品。最後，我們客製化商業化策略，使製劑形式和給藥途徑與分銷管道能力和終端用戶需求相匹配，並確保通訊涵蓋療效和對日常生活的影響。這些舉措共同構成了一個協調一致的計劃，兼顧了短期市場准入和長期品牌永續性。

為了確保解釋的嚴謹性，我們採用了嚴謹的多方面調查方法，包括相關利益者訪談、監管審查、臨床綜合分析和供應鏈風險評估。

本研究採用多學科方法，結合定性和定量證據來源，旨在深入了解失眠治療領域。主要研究包括對關鍵相關人員進行結構化訪談，這些利害關係人包括臨床專家、處方集決策者、採購人員和分銷合作夥伴，以收集有關推廣促進因素、安全顧慮和營運限制等方面的實地觀點。次要研究則利用同行評審文獻、監管指導文件、臨床試驗註冊庫和上市公司披露資訊，對臨床和監管趨勢進行三角驗證。

我們的分析方法包括臨床對比分析、跨治療領域、製劑形式、給藥途徑、分銷管道和終端用戶環境的細分市場分析，以及針對近期政策和關稅變化的供應鏈風險檢驗。我們非常注重透過與多個獨立資訊來源交叉核對和反覆的同儕審查來驗證我們的研究結果。我們的調查方法強調資料來源的透明度和解讀的嚴謹性，以確保我們的結論反映的是當前的實踐模式和現行的監管環境，而非推測性的預測。

摘要重點闡述了以臨床差異化、實證投資、靈活的供應策略和通路為核心的商業化策略，旨在推動持續影響。

總之，失眠治療領域正受到機制特異性臨床進展、安全性和日常功能預期變化以及分銷和醫療服務模式變革的重塑。將產品開發與差異化臨床特徵相結合、投資於真實世界證據並採用靈活的生產和籌資策略的相關人員，將能夠更有效地應對商業性和監管方面的複雜性。此外，整合數位健康模式並制定針對特定管道的商業化計劃，對於擴大治療覆蓋範圍和提高門診及居家照護環境中的用藥依從性至關重要。

展望未來，決策者應持續關注兩方面：一方面是短期准入問題，例如藥品目錄定位和供應鏈韌性；另一方面是長期投資於支持差異化價值的實證醫學證據。這將使各機構能夠在負責任地滿足支付方和臨床醫生需求的同時，建立永續的競爭優勢。後續可執行的建議以及與商業和諮詢資源的客製化合作，將有助於將這些策略方向轉化為能夠帶來可衡量成果的營運計畫。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • Orexin受體拮抗劑的快速成長，得益於真實世界中安全性和有效性證據的持續累積。
  • 將數位療法和認知行為療法模組與失眠藥物結合，以創建個人化治療方案
  • 新冠肺炎相關睡眠感染疾病對處方模式和失眠藥物長期需求的影響
  • 由於擔心成癮性和認知風險，Z類藥物將受到更嚴格的監管審查和上市後監測。
  • 人們對褪黑激素促效劑在兒童和老年人失眠治療策略中的應用越來越感興趣，希望擴大仿單標示外。
  • 非鎮靜性抗焦慮藥物的研發及臨床試驗進展（針對伴隨憂鬱症的失眠）
  • 穿戴式睡眠監測設備和人工智慧驅動的分析技術的出現，將使失眠藥物的劑量能夠即時調整。
  • 新型雙重Orexin受體拮抗劑上市，帶來激烈的藥品目錄競爭與價格壓力。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依藥物類別分類的失眠治療市場

  • 抗組織胺藥
  • 苯二氮平類藥物
  • 褪黑素受體促效劑
  • 非苯二氮平類藥物
    • 依佐匹克隆
    • Zaleplon
    • Zolpidem
  • Orexin受體拮抗劑
    • 達里德雷桑特
    • 倫博雷桑
    • 蘇沃雷桑

9. 依配方分類的失眠治療市場

  • 膠囊
  • 注射
  • 口服懸浮液
  • 舌下片
  • 藥片

第10章 依給藥途徑分類的失眠治療市場

  • 靜脈注射
  • 口服
  • 舌下給藥
  • 經皮

第11章 按分銷管道分類的失眠治療市場

  • 藥局
  • 醫院藥房
    • 私立醫院
    • 公立醫院
  • 網路藥房
    • 通用B2C平台
    • 廠商直銷網站
    • 遠距藥事照護服務
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房
    • 超級市場藥房

第12章：失眠治療市場（依最終用戶分類）

  • 門診治療中心
  • 診所
  • 居家醫療
  • 醫院
    • 私立醫院
    • 公立醫院

第13章：各地區的失眠治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 失眠治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國失眠治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Sanofi SA
    • Sunovion Pharmaceuticals Inc.
    • Merck & Co., Inc.
    • Eisai Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd.
    • Avadel Pharmaceuticals plc
    • Idorsia Ltd.
    • Viatris Inc.
Product Code: MRR-F6513A06BE94

The Insomnia Drugs Market is projected to grow by USD 4.87 billion at a CAGR of 5.91% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.07 billion
Estimated Year [2025] USD 3.25 billion
Forecast Year [2032] USD 4.87 billion
CAGR (%) 5.91%

A concise contextual introduction framing therapeutic innovation, clinical pressures, and commercial drivers that shape the modern insomnia treatment landscape

The insomnia drugs landscape is undergoing rapid evolution driven by scientific advances, shifting patient expectations, and intensifying regulatory attention. This executive summary introduces the critical themes that shape current and near-term decision-making for stakeholders across pharmaceutical development, clinical practice, distribution, and payer engagement. The overview synthesizes therapeutic innovations, changing consumption patterns, and the infrastructure supporting treatment delivery, offering a clear entry point for leaders seeking to align investments with emerging opportunities.

Importantly, this introduction situates insomnia within a broader healthcare context where comorbid psychiatric and cardiometabolic conditions influence both therapeutic choices and adherence. It highlights how pharmacological differentiation, safety profiles, and convenience of administration increasingly determine clinician preference and patient uptake. The section sets expectations for the subsequent analysis by outlining methodological rigor and the multi-dimensional lens-clinical, regulatory, commercial-used to interpret trends. Readers are invited to proceed with a focus on strategic implications rather than historical volume metrics, as the subsequent sections prioritize actionable insights that support portfolio and market-access decisions.

An analysis of paradigm-shifting clinical advances, payer expectations, and care-delivery innovations that are reshaping insomnia drug development and adoption

The insomnia therapeutics environment is experiencing transformative shifts shaped by innovation in mechanism of action, heightened safety expectations, and digital-enabled care pathways. Novel compounds targeting orexin receptors have recalibrated clinical conversations about efficacy and next-day functioning, prompting clinicians to reassess prescribing patterns and risk-benefit trade-offs. Concurrently, advances in formulation science-aimed at improving onset, duration, and tolerability-are influencing how products are positioned across ambulatory and institutional settings.

Meanwhile, payer scrutiny and regulatory guidance are prompting manufacturers to demonstrate differentiated value through real-world evidence and comparative-effectiveness studies. Digital therapeutics and remote patient monitoring are redefining adjunctive treatment models, enabling stepped-care approaches that combine behavioral and pharmacologic interventions. Additionally, patient-centric packaging and alternative routes of administration are gaining attention as adherence drivers. Collectively, these shifts are altering competitive dynamics, funneling investment into targeted R&D, and encouraging strategic partnerships that accelerate time-to-clinic for next-generation insomnia solutions.

How 2025 tariff adjustments and trade dynamics are prompting supply chain redesigns, procurement diversification, and resilience investments across the insomnia drug value chain

Policy and trade actions, including tariff adjustments implemented in 2025, have introduced new variables into global supply chain planning for pharmaceutical manufacturers and distributors. These measures have affected the cost base for certain imported active pharmaceutical ingredients, excipients, and finished formulations, prompting procurement teams to reassess sourcing strategies and contingency inventories. In response, many organizations have accelerated diversification of supplier networks and increased emphasis on nearshoring to reduce exposure to trade-related volatility.

In addition, the tariff landscape has intensified scrutiny of cost-to-serve calculations across distribution channels. Hospital pharmacies and large retail chains have re-evaluated procurement agreements and inventory management protocols to mitigate margin compression. Meanwhile, manufacturers have revisited manufacturing footprints and supply chain resilience investments, prioritizing flexibility in batch sizes and multi-site qualification. Regulatory compliance considerations and quality assurance requirements continue to shape these adjustments, and companies are increasingly balancing tariff-driven cost pressures with commitments to reliability and therapeutic integrity.

Comprehensive segmentation intelligence revealing therapeutic class nuances, formulation and administration distinctions, distribution dynamics, and end-user patterns that inform targeted strategies

Segmentation analysis reveals differentiated drivers of value and demand across therapeutic class, formulation, route of administration, distribution channel, and end-user settings. The drug class dimension encompasses antihistamines, benzodiazepines, melatonin receptor agonists, non-benzodiazepines, and orexin receptor antagonists; within the non-benzodiazepine category, clinically relevant agents such as eszopiclone, zaleplon, and zolpidem demonstrate varying profiles of onset and half-life that influence positioning, while orexin receptor antagonists including daridorexant, lemborexant, and suvorexant have introduced a distinct efficacy and tolerability conversation into prescriber decision-making. These differences drive divergent clinical narratives and promotional strategies, with some classes remaining more attractive for short-term symptom control and others suited for maintenance therapy considerations.

Formulation choices-ranging from capsules, injectables, oral suspensions, sublingual tablets, to tablets-are shaping product differentiation and patient preference, as ease of use and onset characteristics become competitive levers. Route-of-administration distinctions, including intravenous, oral, sublingual, and transdermal options, further influence hospital versus outpatient utilization and the feasibility of certain therapeutic approaches in primary care or acute settings. Distribution channel segmentation highlights the role of drug stores, hospital pharmacies, online pharmacies, and retail pharmacies in shaping access and adherence; within hospital pharmacies, private and public institutions exhibit differing procurement behaviors, while online pharmacies segment into general B2C platforms, manufacturer direct sites, and telepharmacy services, each presenting unique regulatory and commercial dynamics. Retail pharmacy variations-chain, independent, and supermarket pharmacies-affect promotional reach and point-of-sale engagement strategies. End-user segmentation across ambulatory care centers, clinics, home care, and hospitals underscores divergent care pathways; hospitals themselves differentiate into private and public entities with distinct formulary processes and procurement cycles. By integrating these segmentation lenses, stakeholders can better tailor clinical development, marketing, and distribution tactics to match the nuanced needs of targeted prescribers and patients.

Regional dynamics and regulatory diversity across the Americas, Europe, Middle East & Africa, and Asia-Pacific that require adaptive access and distribution strategies for insomnia therapies

Regional dynamics continue to shape product strategy, regulatory planning, and distribution network design. In the Americas, clinical practice patterns and the interplay between private and public payers influence formulary access, while digital health adoption and telepharmacy models are expanding outpatient reach and patient engagement. Market entry considerations in the Americas often revolve around demonstrating differentiation in real-world functioning and safety to secure favorable positioning with both clinicians and payers.

Within Europe, Middle East & Africa, heterogeneous regulatory frameworks and procurement environments demand adaptive market-access strategies that account for national formularies, public hospital procurement, and private-sector variability. Clinicians across these geographies weigh long-term tolerability and comorbidity profiles heavily in prescribing decisions, and reimbursement pathways can vary significantly between public and private systems. In the Asia-Pacific region, rapid uptake of telemedicine, diverse reimbursement mechanisms, and evolving domestic manufacturing capabilities present both opportunities and complexity. Stakeholders are prioritizing localized evidence generation, regulatory alignment strategies, and partnerships with regional distributors to navigate procurement practices and expedite adoption across public and private healthcare settings. Across all regions, supply chain resilience, local regulatory engagement, and culturally informed patient education remain essential components of successful commercialization.

Competitive and corporate maneuvers emphasizing therapeutic differentiation, digital collaborations, lifecycle management, and evidence generation to secure clinical and commercial advantage

Competitive behavior among leading organizations is characterized by targeted R&D investment, alliance formation, and a focus on lifecycle management aimed at sustaining clinical relevance. Companies are leveraging clinical differentiation, such as improved next-day cognitive profiles and minimized dependency risks, to position late-stage and marketed products more favorably with prescribers and payers. Strategic collaborations between pharmaceutical developers and digital health vendors are becoming more commonplace, enabling combined pharmacologic and behavioral offerings that address adherence and long-term outcomes.

Additionally, some manufacturers are optimizing commercialization by tailoring packaging, patient-support programs, and specialty pharmacy partnerships to specific distribution channels and end-user settings. Mergers, acquisitions, and licensing agreements remain tactical options for expanding portfolios or acquiring differentiated mechanisms of action. Across the competitive landscape, there is increasing emphasis on generating post-approval evidence, including real-world studies and registries, to substantiate value claims and support reimbursement negotiations. Operationally, firms are investing in supply chain flexibility and regulatory expertise to accelerate market entry across multiple geographies while maintaining high standards of quality and safety.

Actionable strategic directives for industry leaders to align evidence generation, digital integration, resilient supply chains, and tailored commercialization for sustainable advantage

Industry leaders should prioritize an integrated approach that aligns clinical differentiation with pragmatic market-access strategies and resilient supply chain design. First, invest in targeted evidence generation that demonstrates comparative effectiveness, patient-reported outcomes, and real-world safety to support formulary inclusion and payer dialogues. Secondly, pursue partnerships with digital health providers to create bundled care pathways that improve adherence and extend market reach, particularly in outpatient and home-care settings. Such combined offerings will enhance value propositions to both clinicians and payers.

Concurrently, optimize manufacturing and procurement by diversifying suppliers and qualifying alternate sites to mitigate exposure to trade and tariff-related disruption. Strengthen engagement with hospital formulary committees through tailored value dossiers and locally relevant real-world data to expedite acceptance in both private and public institutions. Finally, tailor commercialization strategies by aligning formulation and route preferences with distribution channel capabilities and end-user needs, ensuring that messaging addresses both efficacy and daily-life impact. Together, these actions create a coherent plan that balances short-term access priorities with long-term brand sustainability.

A rigorous multi-source research methodology integrating stakeholder interviews, regulatory review, clinical synthesis, and supply chain risk assessment to ensure interpretive rigor

This research employed a multi-disciplinary methodology combining qualitative and quantitative evidence sources to build a robust understanding of the insomnia therapeutic landscape. Primary research involved structured interviews with key stakeholders, including clinical experts, formulary decision-makers, procurement leads, and distribution partners, to capture frontline perspectives on adoption drivers, safety concerns, and operational constraints. Secondary research utilized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public company disclosures to triangulate clinical and regulatory trends.

Analytical techniques included comparative clinical profiling, segmentation mapping across therapeutic class, formulation, route of administration, distribution channel, and end-user settings, and supply chain risk assessment focused on recent policy and tariff developments. Care was taken to validate insights through cross-referencing multiple independent sources and through iterative expert review. The methodology emphasizes transparency in data sourcing and interpretive rigor, ensuring that conclusions reflect current practice patterns and the prevailing regulatory landscape rather than speculative projections.

A concluding synthesis emphasizing clinical differentiation, evidence investment, flexible supply strategies, and channel-focused commercialization to drive sustainable impact

In conclusion, the insomnia drugs domain is being reshaped by mechanism-specific clinical advances, evolving expectations for safety and daily functioning, and shifts in distribution and care-delivery models. Stakeholders who align product development with differentiated clinical profiles, invest in real-world evidence, and adopt flexible manufacturing and procurement strategies will be better positioned to navigate commercial and regulatory complexity. Additionally, integrating digital health modalities and designing channel-specific commercialization plans will be critical to expanding reach and improving adherence in outpatient and home-care settings.

Moving forward, decision-makers should maintain a dual focus on near-term access imperatives-such as formulary positioning and supply chain resilience-and longer-term investments in evidence that supports differentiated value. By doing so, organizations can create durable competitive advantage while responding responsibly to payer and clinician priorities. The subsequent actionable recommendations and tailored engagement with sales and advisory resources can help translate these strategic directions into operational plans that deliver measurable outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid growth of orexin receptor antagonists supported by emerging real-world safety and efficacy evidence
  • 5.2. Integration of digital therapeutics and cognitive behavioral therapy modules with insomnia drugs for personalized treatment pathways
  • 5.3. Impact of COVID-19-induced sleep disturbances on prescription patterns and long-term demand for insomnia medications
  • 5.4. Regulatory scrutiny and post-marketing surveillance intensification for Z-drugs amid dependency and cognitive risk concerns
  • 5.5. Surging interest in melatonin receptor agonists for expanding off-label use in pediatric and geriatric insomnia management strategies
  • 5.6. Development and clinical trial advancements of non-sedative anxiolytic compounds targeting insomnia with comorbid depression
  • 5.7. Emergence of wearable sleep monitoring devices and AI-driven analytics guiding real-time dose adjustment of insomnia drugs
  • 5.8. Market entry of novel dual orexin receptor antagonists driving competitive formulary placement and pricing pressures

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Insomnia Drugs Market, by Drug Class

  • 8.1. Antihistamines
  • 8.2. Benzodiazepines
  • 8.3. Melatonin Receptor Agonists
  • 8.4. Non-Benzodiazepines
    • 8.4.1. Eszopiclone
    • 8.4.2. Zaleplon
    • 8.4.3. Zolpidem
  • 8.5. Orexin Receptor Antagonists
    • 8.5.1. Daridorexant
    • 8.5.2. Lemborexant
    • 8.5.3. Suvorexant

9. Insomnia Drugs Market, by Formulation

  • 9.1. Capsules
  • 9.2. Injectables
  • 9.3. Oral Suspensions
  • 9.4. Sublingual Tablets
  • 9.5. Tablets

10. Insomnia Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Sublingual
  • 10.4. Transdermal

11. Insomnia Drugs Market, by Distribution Channel

  • 11.1. Drug Stores
  • 11.2. Hospital Pharmacies
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Online Pharmacies
    • 11.3.1. General B2C Platforms
    • 11.3.2. Manufacturer Direct Sites
    • 11.3.3. Telepharmacy Services
  • 11.4. Retail Pharmacies
    • 11.4.1. Chain Pharmacies
    • 11.4.2. Independent Pharmacies
    • 11.4.3. Supermarket Pharmacies

12. Insomnia Drugs Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Clinics
  • 12.3. Home Care
  • 12.4. Hospitals
    • 12.4.1. Private Hospitals
    • 12.4.2. Public Hospitals

13. Insomnia Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Insomnia Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Insomnia Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Sanofi S.A.
    • 16.3.2. Sunovion Pharmaceuticals Inc.
    • 16.3.3. Merck & Co., Inc.
    • 16.3.4. Eisai Co., Ltd.
    • 16.3.5. Takeda Pharmaceutical Company Limited
    • 16.3.6. Johnson & Johnson
    • 16.3.7. Teva Pharmaceutical Industries Ltd.
    • 16.3.8. Avadel Pharmaceuticals plc
    • 16.3.9. Idorsia Ltd.
    • 16.3.10. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INSOMNIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. INSOMNIA DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. INSOMNIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INSOMNIA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INSOMNIA DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INSOMNIA DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2024 (USD MILLION)

TABLE 334